Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MTI980 is a lipid-based oral formulation of **estetrol** (E4), a naturally occurring estrogen, developed by **TRX Biosciences** in collaboration with **Mithra Pharmaceuticals**. The drug utilizes TRX Biosciences' proprietary **TRX™ technology**, which is designed to enhance the oral bioavailability and potentially the blood-brain barrier penetration of lipophilic compounds. MTI980 is being developed for the treatment of **central nervous system (CNS) diseases**, with a primary focus on **neonatal hypoxic-ischemic encephalopathy (HIE)**. Estetrol acts as a **Native Estrogen with Selective action in Tissues (NEST)**, exhibiting agonist activity on estrogen receptors in the brain, which is thought to provide neuroprotective effects. It is currently in **Phase 2/3** development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MTI980.